Clinically Relevant Response and Remission Outcomes in Cariprazine-Treated Patients With Bipolar I Disorder

Rates of response and remission are measures that endorse the clinical significance of treatment. Cariprazine is FDA-approved for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Post hoc analyses of pooled data from 3 pivotal trials of cariprazine in manic/mixed episodes associated with bipolar I disorder were conducted to investigate the effect of cariprazine on various criteria of response and remission.
Source: Journal of Affective Disorders - Category: Neurology Authors: Tags: Research paper Source Type: research